The absence of thrombocytopenia, increase of serum IL-6, serum vascular endothelial growth factor, serum alkaline phosphatase, or adrenal involvement may lower the possibility of TAFRO syndrome [18,19]. The gene discussed is IL6; the disease is Castleman-Kojima disease.